Reports

Zumiez Inc. announced its fiscal 2024 fourth quarter results, showing a 5.9% increase in comparable sales and a significant improvement in net income to $14.8 million, or $0.78 per share, compared to a net loss in the prior year. The company also reported a 190 basis point increase in gross margin.

• Fourth quarter comparable sales increased by 5.9%.
• Gross margin for the fourth quarter increased by 190 basis points to 36.2%.

Atara Biotherapeutics has renegotiated a $9.0 million milestone payment to HealthCare Royalty (HCRx), extending the due date from June 2026 to January 2028. This move is intended to provide the company with greater financial flexibility as it addresses FDA concerns regarding tabelecleucel (tab-cel) following a recent Complete Response Letter (CRL).

• Renegotiated a $9.0 million one-time milestone payment due date with HCRx, extending it to January 1, 2028.
• Issued a warrant to HCRx for the purchase of up to 400,000 shares of common stock at an exercise price of $0.0001 per share.